Category: Cancer

Cancer

Medicare Expands Coverage for NeoGenomics RaDaR ST Assay to Include Immunotherapy Monitoring

Medicare has expanded coverage for NeoGenomics’ RaDaR ST MRD assay to include monitoring immunotherapy response in patients with late-stage solid tumors.

Cancer

LabPMM Launches Global KMT2A MRD Testing Service for Acute Leukemia

LabPMM, a subsidiary of Invivoscribe, has launched a global digital PCR KMT2A MRD testing service for acute leukemia, supporting menin inhibitor development and molecular monitoring needs for clinical and biopharma partners.

Cancer

Cancer Detection Test Receives Regulatory Marking for Use in Great Britain

Personalis has received UKCA marking for its NeXT Personal Dx test, enabling clinical use of its minimal residual disease detection technology across Great Britain, the company announced.

Building a Better Picture of Cancer

Aug 4, 2026 | Cancer, Lab Automation, Molecular Diagnostics

Clinical labs are adopting broader cancer diagnostics—including whole-genome sequencing and multi-omic testing—to deliver more comprehensive molecular insights and improve disease monitoring.

AI Blood Assay Detects Liver Cancer Across Diverse International Populations

Aug 4, 2026 | Cancer, Molecular Diagnostics

Researchers at Johns Hopkins validated an AI-powered blood test that accurately detects liver cancer in diverse populations, using the DELFI platform to analyze cell-free DNA fragments.

GenomOncology and PacBio Launch Integrated Oncology Sequencing Workflow

Aug 4, 2026 | Cancer, Company News, Molecular Diagnostics

GenomOncology and PacBio have introduced an integrated workflow for somatic whole-genome sequencing in oncology, combining PacBio’s HiFi WGS analysis with GenomOncology’s reporting platform for standardized clinical lab reporting.

Liquid Biopsy Predicts Immunotherapy Benefit Within Weeks in Advanced Lung Cancer

Aug 4, 2026 | Lung Cancer

A Johns Hopkins study finds that a single liquid biopsy within nine weeks of immunotherapy start can predict long-term survival in advanced lung cancer, providing results months earlier than standard imaging.

Study Highlights Need for Family History in BRCA Test Interpretation

Aug 4, 2026 | Breast

A Cedars-Sinai study in JAMA Network Open reports women testing negative for BRCA mutations but with a family cancer history face a 25% lifetime breast cancer risk, underscoring the importance of family history in risk assessment.

Study Validates Proteomic Blood Test for Early-Stage Breast Cancer Detection

Aug 3, 2026 | Breast

A peer-reviewed study validates Astrin Biosciences’ Certitude test, which uses proteomics and machine learning to detect early-stage breast cancer with 92.6% sensitivity and 92.3% specificity.

10x Genomics and Lausanne University Hospital Collaborate on Cancer Diagnostic Research

Aug 3, 2026 | Cancer, Company News, Molecular Diagnostics

10x Genomics and Lausanne University Hospital have begun a multi-year study using single cell and spatial technologies to identify biomarkers predicting treatment response in patients with advanced solid tumors.

YD Bio Launches Cross-Border Cancer Testing Pilot in Canada

Jul 31, 2026 | Accreditation, Cancer, Company News

YD Bio and Numia Health have launched a six-month pilot in British Columbia to evaluate cross-border blood-based cancer testing, supporting up to 50 patient episodes with laboratory analysis performed at a CLIA-certified U.S. facility.

Nabsys and Indiana University Collaborate on Electronic Genome Mapping for Blood Cancers

Jul 31, 2026 | Leukemia

Nabsys and Indiana University School of Medicine have launched a multi-year collaboration to develop electronic genome mapping applications for acute myeloid leukemia and myelodysplastic syndromes.

RNA-Based Testing Improves Detection of MET Exon 14 Skipping in Lung Cancer

Jul 30, 2026 | Lung Cancer, Molecular Diagnostics

RNA-based testing improves detection of MET exon 14 skipping in NSCLC, identifying mutations missed by DNA-only assays, according to new research. Findings may impact eligibility for targeted therapies.

Labcorp Launches Consumer Genetic Health Panel for Hereditary Risk Assessment

Jul 27, 2026 | Cancer, Cardiovascular, Molecular Diagnostics

Labcorp has announced the upcoming launch of the Marker by Labcorp Genetic Health Panel, which will analyze 163 genes linked to over 100 medically actionable conditions, with results supported by licensed genetic counselors.

Thermo Fisher Highlights New FDA-Cleared Diagnostics at ADLM 2026

Jul 27, 2026 | Cancer, Mass Spectrometry, Molecular Diagnostics

The company is showcasing newly cleared tests and platforms for multiple myeloma, lung cancer, connective tissue disease, and other laboratory applications.

Researchers Link Gene Variant to Aggressive Prostate Cancer Risk

Jul 24, 2026 | Prostate

Researchers report that inherited CDK12 gene variants may increase risk for early, aggressive prostate cancer, suggesting inclusion of CDK12 in hereditary screening panels could improve risk identification in men.

Ibex Earns European Certification for Complete Breast Pathology AI Suite

Jul 24, 2026 | Anatomic Pathology, Breast, Digital Pathology

Ibex Medical Analytics has received IVDR certification for its breast cancer diagnostic tools, completing regulatory approval for ER, PR, and Ki67 tests, according to a company press release.

Cancer Cell Diagnostics Launches New Blood Test for Cancer Profiling

Jul 23, 2026 | Cancer, Molecular Diagnostics

The test uses intact circulating tumor cells instead of cell-free DNA fragments to analyze more than 500 genes and identify tumor markers.